Paul D. Thompson, MD

View Faculty Disclosure Statement

Director, Division of Cardiology
Hartford Hospital
Hartford, Connecticut
Professor of Medicine
University of Connecticut
Hartford, Connecticut

Biographical Sketch

Paul D. Thompson, MD, is chief of cardiology and director of the Preventive Cardiology Program and of Cardiovascular Research at Hartford Hospital, Hartford, Connecticut, and professor of medicine at the University of Connecticut in Farmington. He was professor of medicine at the University of Pittsburgh from 1992 to 1997 and on the faculty of Brown University from 1978 to 1992. Dr. Thompson received a medical degree from Tufts Medical School in Boston. He served as a medical intern and resident, as well as a cardiology catheterization fellow, at Tufts-New England Medical Center before completing his training in cardiology at Stanford Medical Center.
Dr. Thompson has been an author of more than 140 scientific articles on topics including the effects of exercise training on preventing and treating heart disease, the risk of sudden death during exercise, and the effects of exercise on lipid metabolism. These research efforts have been supported by grants from the American Heart Association, the National Heart, Lung, and Blood Institute, and the National Institute of Child Health and Human Development. He is also an associate editor of the Textbook of Cardiovascular Medicine and the editor of the book Exercise and Sports Cardiology. He is a past president of the American College of Sports Medicine.
Dr. Thompson's present research interests are the effects of statins on skeletal muscle gene expression and how genetic variants affect the response to exercise training. These projects are supported by the Donaghue Foundation and the National Institutes of Health.

Faculty Disclosure Statement

Dr. Thompson has received grant support related to research activities from AstraZeneca Pharmaceuticals LP, Merck & Co., Inc., and Pfizer Inc.  He has received honoraria related to Speakers Bureau activities from AstraZeneca Pharmaceuticals LP; KOS Pharmaceuticals; Merck & Co., Inc.; Pfizer Inc.; and Schering-Plough Corporation.  He has significant holdings in Pfizer Inc., Schering-Plough Corporation, and Merck & Co, Inc.